Research progress on the role of hexokinase 2 in the pathogenesis of hepatocellular carcinoma

doi:10.3760/cma.j.cn441417-20250317-17006

Abstract

Abstract:

The mortality rate of hepatocellular carcinoma (HCC) ranks third among all malignant tumors worldwide, and its incidence is increasing year by year. The research on the pathogenesis of HCC has always been of great concern. In recent years, cancer metabolism research has become a new research hotspot in the field of oncology. Among them, the changes in cellular metabolism are not only the cause of cancer occurrence, but also the result of tumor progression. Hexokinase (HK) ２, as a key metabolic enzyme, is closely related to the pathogenesis and progression of HCC. Moreover, HK2 inhibitors play a significant role in regulating the metabolic activities of cancer cells. This reveals the great potential of HK2 inhibitors in combating malignant tumors. This article reviews the biological role of HK2 in HCC, with the aim of providing new ideas for the treatment of HCC.

Key words:

Hepatocellular carcinoma, Hexokinase 2, Pathogenesis, Cellular metabolism, Hexokinase 2 inhibitors, Progress

摘要：

肝细胞癌（HCC）的病死率在全球恶性肿瘤中居第三位，且发病率呈逐年上升趋势，其发病机制的研究一直备受关注。近年来，癌症代谢研究已成为肿瘤学领域的新研究热点。其中，细胞代谢的改变不仅是癌症发生的原因，也是肿瘤进展的结果。己糖激酶（HK）2作为一种关键代谢酶，其过表达与HCC发病机制及病情进展密切相关，且HK2抑制剂在调控癌细胞代谢活动方面发挥重要作用，这揭示了HK2抑制剂在对抗恶性肿瘤方面的巨大潜力。现就HK2在HCC中的生物学作用进行综述，以期为HCC治疗提供新思路。

关键词:

肝细胞癌, 己糖激酶2, 发病机制, 细胞代谢, 己糖激酶2抑制剂, 进展

Dong Yunhong, Gong Keke, Lan Yongting.

Research progress on the role of hexokinase 2 in the pathogenesis of hepatocellular carcinoma [J]. International Medicine and Health Guidance News, 2025, 31(17): 2847-2851.

董云红龚珂珂兰永廷.

己糖激酶2调控肝细胞癌发病机制的研究进展 [J]. 国际医药卫生导报, 2025, 31(17): 2847-2851.

References

[1] 姚宝乐, 朱晓娟, 温望文, 等. TCF7L2及经典Wnt信号通路在肝癌中作用的研究进展[J]. 国际医药卫生导报, 2023, 29(2): 149-153. DOI: 10.3760/cma.j.issn.1007-1245.2023.02.001.
[2] 王琪.靶向代谢重编程改善肝细胞癌耐药的策略及其机制研究[D].长春:吉林大学,2024.DOI:10.27162/d.cnki.gjlin.2024.000464.
[3] DeWaal D, Nogueira V, Terry AR, et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin[J]. Nat Commun, 2018,9(1):446. DOI: 10.1038/s41467-017-02733-4.
[4] 刘伟,申昌军,朱帅,等.己糖激酶-2的表达对肝癌根治术后患者的预后意义[J].河北医药,2019,41(1):28-32.DOI:10.3969/j.issn.1002-7386.2019.01.006.
[5] Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2020, 39(1):126. DOI: 10.1186/s13046-020-01629-4.
[6] Ciscato F, Ferrone L, Masgras I, et al. Hexokinase 2 in cancer: a prima donna playing multiple characters[J]. Int J Mol Sci, 2021,22(9):4716. DOI: 10.3390/ijms22094716.
[7] Mathupala SP, Ko YH, Pedersen PL. Hexokinase Ⅱ: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria [J]. Oncogene, 2006, 25(34): 4777-4786.DOI: 10.1038/sj.onc.1209603.
[8] Wang L, Yang Q, Peng S, et al. The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells[J]. Onco Targets Ther, 2019, 12:5359-5373. DOI: 10.2147/OTT.S212465.
[9] Xu S, Herschman HR. A tumor agnostic therapeutic strategy for hexokinase 1-null/hexokinase 2-positive cancers[J]. Cancer Res, 2019, 79(23):5907-5914. DOI: 10.1158/0008-5472.CAN-19-1789.
[10] Czaja MJ, Ding WX, Donohue TM, et al. Functions of autophagy in normal and diseased liver [J]. Autophagy, 2014, 9(8): 1131-1158. DOI: 10.4161/auto.25063.
[11] Jiao L, Zhang HL, Li DD, et al. Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2) [J]. Autophagy, 2017, 14(4): 671-684. DOI: 10.1080/15548627.2017.1381804.
[12] Jin F, Wang Y, Zhu Y, et al. The miR-125a/HK2 axis regulates cancer cell energy metabolism reprogramming in hepatocellular carcinoma [J]. Sci Rep, 2017, 7(1):3089. DOI: 10.1038/s41598-017-03407-3.
[13] Ding Z, Guo L, Deng Z, et al. Circ-PRMT5 enhances the proliferation, migration and glycolysis of hepatoma cells by targeting miR-188-5p/HK2 axis [J]. Ann Hepatol, 2020, 19(3): 269-279. DOI: 10.1016/j.aohep.2020.01.002.
[14] Makino Y, Hikita H, Kato S, et al. STAT3 is activated by CTGF-mediated tumor-stroma cross talk to promote HCC progression [J]. Cell Mol Gastroenterol Hepatol, 2023, 15(1): 99-119. DOI: 10.1016/j.jcmgh.2022.09.006.
[15] Li Y, Song Z, Han Q, et al. Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis [J]. Mol Oncol, 2022, 16(15): 2861-2880. DOI: 10.1002/1878-0261.13263.
[16] Guo W, Qiu Z, Wang Z, et al. MiR‐199a‐5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer [J]. Hepatology, 2015, 62(4): 1132-1144. DOI: 10.1002/hep.27929.
[17] Zhang T, Zhu X, Wu H, et al. Targeting the ROS/PI3K/AKT/HIF‐1α/HK2 axis of breast cancer cells: combined administration of polydatin and 2‐deoxy‐d‐glucose [J]. J Cell Mol Med, 2019, 23(5): 3711-3723. DOI: 10.1111/jcmm.14276.
[18] Lee HG, Kim H, Son T, et al. Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma[J]. Oncotarget, 2016, 7(27): 41798-41810. DOI: 10.18632/oncotarget.9723.
[19] Sun Z, Tan Z, Peng C, et al. HK2 is associated with the Warburg effect and proliferation in liver cancer: targets for effective therapy with glycyrrhizin [J]. Mol Med Rep, 2021, 23(5):343. DOI: 10.3892/mmr.2021.11982.
[20] Ciscato F, Filadi R, Masgras I, et al. Hexokinase 2 displacement from mitochondria‐associated membranes prompts Ca2+‐dependent death of cancer cells [J]. EMBO Rep, 2020, 21(7): e49117. DOI: 10.15252/embr.201949117.
[21] Kim W, Yoon JH, Jeong JM, et al. Apoptosis-inducing antitumor efficacy of hexokinase Ⅱ inhibitor in hepatocellular carcinoma [J]. Mol Cancer Ther, 2007, 6(9): 2554-2562. DOI: 10.1158/1535-7163.Mct-07-0115.
[22] Zhu Z, Jiang W, McGinley JN, et al. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro[J]. Cancer Res, 2005, 65(15): 7023-7030. DOI: 10.1158/0008-5472.CAN-05-0453.
[23] Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy[J]. Pharmacol Res, 2019, 150:104511. DOI: 10.1016/j.phrs.2019.104511.
[24] Meng YM, Jiang X, Zhao X, et al. Hexokinase 2-driven glycolysis in pericytes activates their contractility leading to tumor blood vessel abnormalities[J]. Nat Commun, 2021, 12(1):6011. DOI: 10.1038/s41467-021-26259-y.
[25] Garcia SN, Guedes RC, Marques MM. Unlocking the potential of HK2 in cancer metabolism and therapeutics[J]. Curr Med Chem, 2019, 26(41):7285-7322. DOI: 10.2174/0929867326666181213092652.
[26] Yoo JJ, Yu SJ, Na J, et al. Hexokinase-Ⅱ inhibition synergistically augments the anti-tumor efficacy of sorafenib in hepatocellular carcinoma [J]. Int J Mol Sci, 2019, 20(6):1292. DOI: 10.3390/ijms20061292.